GREENWICH LIFESCIENCES, INC. Financing Cash Flow
GREENWICH LIFESCIENCES, INC. (GLSI) reported Financing Cash Flow of $9.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $310.66K, a 88.09% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $9.03M, a 1733.77% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $5.55M, a 4452.04% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.35M, a 183.82% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2025 was $12.00M, a 174.64% increase from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2024 was $4.37M.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2022 was -$7.54M, a 365.79% decline from fiscal 2021.
- GREENWICH LIFESCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2021 was $2.84M, a 90.49% decline from fiscal 2020.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $310.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $9.34M 10-Q · filed 2026-08-11 | $14.89M derived: sum of 3 quarters · filed 2026-08-11 | $18.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $9.03M 10-Q · filed 2026-06-04 | $14.58M derived: sum of 2 quarters · filed 2026-06-04 | $17.93M derived: sum of 3 quarters · filed 2026-06-04 | $20.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $8.90M derived: sum of 2 quarters · filed 2026-06-01 | $11.51M derived: sum of 3 quarters · filed 2026-08-11 | $12.00M 10-K · filed 2026-06-01 |
| 2025-09-30 | $3.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.96M derived: sum of 2 quarters · filed 2026-08-11 | $6.45M 10-Q · filed 2025-11-14 | $6.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.10M 10-Q · filed 2026-08-11 | $3.22M derived: sum of 3 quarters · filed 2026-08-11 | $4.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $492.42K 10-Q · filed 2026-06-04 | $614.25K derived: sum of 2 quarters · filed 2026-06-04 | $1.80M derived: sum of 3 quarters · filed 2026-06-04 | $4.56M derived: sum of 4 quarters · filed 2026-06-04 |
| 2024-12-31 | $121.83K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $1.30M derived: sum of 2 quarters · filed 2026-06-01 | $4.07M derived: sum of 3 quarters · filed 2026-06-01 | $4.37M 10-K · filed 2026-06-01 |
| 2024-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.95M derived: sum of 2 quarters · filed 2025-11-14 | $4.25M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $3.07M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $299.12K 10-Q · filed 2025-05-20 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $0.00 derived: sum of 2 quarters · filed 2024-04-15 | -$2.02M derived: sum of 3 quarters · filed 2024-04-15 | -$7.54M 10-K · filed 2024-04-15 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-19 | -$2.02M derived: sum of 2 quarters · filed 2023-10-19 | -$7.54M 10-Q · filed 2023-10-19 | -$6.97M derived: sum of 4 quarters · filed 2023-10-19 |
| 2022-06-30 | -$2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$7.54M 10-Q · filed 2023-08-21 | -$6.97M derived: sum of 3 quarters · filed 2023-08-21 | -$6.97M derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | -$5.51M 10-Q · filed 2023-05-22 | -$4.95M derived: sum of 2 quarters · filed 2023-05-22 | -$4.95M derived: sum of 3 quarters · filed 2023-05-22 | -$4.95M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $562.60K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $562.60K derived: sum of 2 quarters · filed 2023-03-31 | $562.60K derived: sum of 3 quarters · filed 2023-03-31 | $2.84M 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $2.27M 10-Q · filed 2022-11-14 | $25.87M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $2.27M 10-Q · filed 2022-08-15 | $25.87M derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $2.27M 10-Q · filed 2022-05-20 | $25.87M derived: sum of 2 quarters · filed 2022-05-20 | ||
| 2020-12-31 | $23.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $29.81M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $6.21M 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $215.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |